Electronic trial master file

Last updated

An electronic trial master file (eTMF) is a trial master file in electronic (digital content) format. It is a type of content management system for the pharmaceutical industry, providing a formalized means of organizing and storing documents, images, and other digital content for pharmaceutical clinical trials that may be required for compliance with government regulatory agencies. The term eTMF encompasses strategies, methods and tools used throughout the lifecycle of the clinical trial regulated content. An eTMF system consists of software and hardware that facilitates the management of regulated clinical trial content. Regulatory agencies have outlined the required components of eTMF systems that use electronic means to store the content of a clinical trial, requiring that they include: Digital content archiving, security and access control, change controls, audit trails, and system validation.

Contents

History and background

In order to comply with government regulatory requirements surrounding BioPharma clinical trials, every organization involved in regulated clinical trials must maintain and store certain 'essential documents' related to the clinical trial to ensure regulatory compliance. Depending on the regulatory jurisdiction, this information is typically stored in the trial master file or TMF. [1] [2] The TMF has historically been composed primarily of paper documents, images and media captured centrally in physical file cabinets. [3]

In order to lower costs and to expedite the clinical trials approval processes, government agencies involved in regulating clinical trials such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have been developing technology initiatives. In the U.S., the FDA created regulation CFR 21 Part 11 which supports the use of electronic records, digital media and digital signatures in clinical trials. [4] In Europe, the European Medicines Agency has issued policies that support the use of digital signatures in clinical trials. [5]

In clinical trials and healthcare, enterprises with manual paper-based systems are seeking to transition to automated electronic enterprise content management (ECM) systems to ensure higher levels of regulatory compliance for reduced business risk. [6] As a result of the FDA's Part 11 policy supporting the use of electronic records and digital signatures in lieu of paper, US organizations involved in U.S. clinical trials can move from a paper-based TMF to an electronic TMF (eTMF), and still be in compliance with FDA regulatory policies.

Definition

The definition of what comprises an eTMF is defined by the regulatory agency with jurisdiction over the clinical trial. In Europe, the EMA has recently defined an eTMF as follows: 'An eTMF can contain digital documents in their original format, potentially with digital signatures, or records that have been converted from another format, such as paper documents that have been converted to digital images, which may contain wet-ink signatures. The metadata applied to documents is recommended be formally defined to ensure consistency across all documents.' [7] At the time of this article no formal US FDA requirement exists for the use of an eTMF system in a clinical trial. However, if a clinical trial elects to store trial master file 'essential documents' in electronic format, then the eTMF system used to store those files is subject to regulatory controls specified under FDA Title 21 CFR Part 11. [8] [9]

Required components of an eTMF system

With respect to the FDA, the required components, controls and policies for an eTMF used in US based clinical trials follow US FDA CFR 21 Part 11 requirements. In August 2003, the FDA issued additional guidance to the industry that outlines the required components, controls, policies and validation required for electronic systems and electronic signatures. According to the FDA, systems used to store electronic records or documents are generally subject to the following controls and requirements: [10]

Although the FDA and other regulatory agencies have defined the requirements for electronic document and record systems that store clinical trial essential documents, no government agency has defined how eTMF content should be classified, or the standards for metadata that may used in content indexing, or the electronic format(s) that should be used to model, store or exchange eTMF data. As a result of the lack of a standard to represent eTMF content, eTMF information interoperability and content exchange between systems and applications is inefficient.

eTMF standards initiative

In an effort to assure interoperability of eTMF data among clinical trial stakeholders, in September 2013 non-profit CareLex and SureClinical initiated an eTMF standards initiative under the OASIS open standards development organization for the development of a global eTMF standard. The initiative, known as the OASIS eTMF Standard Technical Committee, has a stated objective to "define an open, internationally recognized standard that will assure information interoperability among clinical trial stakeholders in the BioPharma industry." [11] [12] According to minutes from the OASIS eTMF Standard Technical Committee (TC), the standards initiative is coordinating the efforts of clinical trial sponsors, CRO’s (Contract Research Organizations), academic research organizations, and vendors to develop an ISO standard. [13]

As of July 2014, a list of members in the OASIS eTMF Standard TC includes CareLex, Forte Research, Fujitsu, HL7, Mayo Clinic, NextDocs (since acquired by Aurea), Oracle, Paragon Solutions (since acquired by CGI), Phlexglobal, SAFE-BioPharma, SterlingBio, and SureClinical. [14]

Information on the charter for the OASIS eTMF Standard TC is available for download through OASIS. [15] Membership in the OASIS eTMF Standard TC was opened to anyone in September 2013; membership in the OASIS eTMF Standard TC remains open to anyone who wishes to join and the work of the TC is open to public comment and review. All work of the OASIS eTMF standard TC is available freely under OASIS open source IPR policies. [16] [17] [18] The eTMF Technical Committee closed on 17 November 2017 without publishing a standard and is no longer active.

In June 2018, the TMF Reference Model project team published a specification [8] and an example XML exchange file [9] for an eTMF Exchange Mechanism Standard [10] at the DIA Global Meeting in Boston, USA. Use of this standard will help facilitate the exchange of TMF content between systems.

Recent developments

In February 2013, the EMA (European Medicines Agency) created a draft guideline document that recognizes the importance and legal equivalence of the TMF and the eTMF, and provided guidance to organizations implementing TMFs and eTMF systems. In the guideline document, EMA inspectors state that paper TMF documents may be stored in electronic eTMF systems, and after this process, that the paper may be destroyed. The use of eTMF systems for electronic storage is fully supported by the EMA in clinical trials as a replacement for paper. In a cautionary statement, the agency cites quality problems with TMFs and eTMFs due to document quality and discrepancies such as missing pages, improper labeling or missing documents. [19]

A recent study shows that the adoption of eTMF solutions is accelerating - with more than 50% of investigative site expected to have access to a sponsor/CRO eTMF application within three years. [20]

Related Research Articles

A document management system (DMS) is a system used to receive, track, manage and store documents and reduce paper. Most are capable of keeping a record of the various versions created and modified by different users. In the case of the management of digital documents such systems are based on computer programs. The term has some overlap with the concepts of content management systems. It is often viewed as a component of enterprise content management (ECM) systems and related to digital asset management, document imaging, workflow systems and records management systems.

The Organization for the Advancement of Structured Information Standards is a nonprofit consortium that works on the development, convergence, and adoption of open standards for cybersecurity, blockchain, Internet of things (IoT), emergency management, cloud computing, legal data exchange, energy, content technologies, and other areas.

The Open Document Format for Office Applications (ODF), also known as OpenDocument, is an open file format for spreadsheets, charts, presentations and word processing documents using ZIP-compressed XML files. It was developed with the aim of providing an open, XML-based file format specification for office applications. It is also the default format for documents in typical Linux distributions.

Common Technical Document

The Common Technical Document (CTD) is a set of specifications for an application dossier for the registration of Medicines and designed to be used across Europe, Japan and the United States and beyond.

Universal Business Language (UBL) is an open library of standard electronic XML business documents for procurement and transportation such as purchase orders, invoices, transport logistics and waybills. UBL was developed by an OASIS Technical Committee with participation from a variety of industry data standards organizations. UBL is designed to plug directly into existing business, legal, auditing, and records management practices. It is designed to eliminate the re-keying of data in existing fax- and paper-based business correspondence and provide an entry point into electronic commerce for small and medium-sized businesses.

Enterprise content management (ECM) extends the concept of content management by adding a timeline for each content item and, possibly, enforcing processes for its creation, approval and distribution. Systems using ECM generally provide a secure repository for managed items, analog or digital. They also include one methods for importing content to bring manage new items, and several presentation methods to make items available for use. Although ECM content may be protected by digital rights management (DRM), it is not required. ECM is distinguished from general content management by its cognizance of the processes and procedures of the enterprise for which it is created.

The Clinical Data Interchange Standards Consortium (CDISC) is a standards developing organization (SDO) dealing with medical research data linked with healthcare, to "enable information system interoperability to improve medical research and related areas of healthcare". The standards support medical research from protocol through analysis and reporting of results and have been shown to decrease resources needed by 60% overall and 70–90% in the start-up stages when they are implemented at the beginning of the research process.

The electronic common technical document (eCTD) is an interface and international specification for the pharmaceutical industry to agency transfer of regulatory information. The specification is based on the Common Technical Document (CTD) format and was developed by the International Council for Harmonisation (ICH) Multidisciplinary Group 2 Expert Working Group.

Title 21 CFR Part 11 is the part of Title 21 of the Code of Federal Regulations that establishes the United States Food and Drug Administration (FDA) regulations on electronic records and electronic signatures (ERES). Part 11, as it is commonly called, defines the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records.

Good clinical data management practice (GCDMP) is the current industry standards for clinical data management that consist of best business practice and acceptable regulatory standards. In all phases of clinical trials, clinical and laboratory information must be collected and converted to digital form for analysis and reporting purposes. The U.S. Food and Drug Administration and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use have provided specific regulations and guidelines surrounding this component of the drug and device development process. The effective, efficient and regulatory-compliant management of clinical trial data is an essential component of drug and device development.

Content Management Interoperability Services (CMIS) is an open standard that allows different content management systems to inter-operate over the Internet. Specifically, CMIS defines an abstraction layer for controlling diverse document management systems and repositories using web protocols.

The following outline is provided as an overview of and topical guide to clinical research:

Good documentation practice is a term in the pharmaceutical and medical device industries to describe standards by which documents are created and maintained. While some GDP / GDocP standards are codified by various competent authorities, others are not but are considered cGMP. Some competent authorities release or adopt guidelines, and they may include non-codified GDP / GDocP expectations. While not law, authorities will inspect against these guidelines and cGMP expectations in addition to the legal requirements and make comments or observations if departures are seen. In the past years, the application of GDocP is also expanding to cosmetic industry, excipient and ingredient manufacturers.

ePharmaSolutions (ePS), as a contract research organization, is an American clinical research provider. The solutions include proprietary software applications and global clinical services that focus on the major areas of clinical study delays.

A clinical trial portal is a web portal or enterprise portal that primarily serves sponsors and investigators in a clinical trial. Clinical portals can be developed for a particular study, however study-specific portals may be part of larger, clinical sponsor or Contract Research Organization (CRO) portals that cover multiple trials. A clinical portal is typically developed by a sponsor or CRO to facilitate centralized access to relevant information, documentation and online applications by investigational sites participating in a trial, as well as for the monitors, study managers, data managers, medical, safety and regulatory staff that help plan, conduct, manage and review the trial.

In order to comply with government regulatory requirements pertinent to clinical trials, every organization involved in clinical trials must maintain and store certain documents, images and content related to the clinical trial. Depending on the regulatory jurisdiction, this information may be stored in the trial master file or TMF, which today takes the form of an electronic trial master file (eTMF). The International Conference on Harmonization (ICH) published a consolidated guidance for industry on Good Clinical Practice in 1996 with the objective of providing a unified standard for the European Union, Japan, and the United States of America to facilitate mutual acceptance of clinical data by the regulatory authorities in those jurisdictions. This guidance document established the requirement across all ICH regions to establish trial master files containing essential documents that individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced.[2] In some jurisdictions, for example the USA, there is no specific requirement for a trial master file. However, if the regulatory authority requires ICH GCP to be followed, then there is consequently a requirement to create and maintain a trial master file.[2]

Guidances for statistics in regulatory affairs are applicable to the pharmaceutical industry and medical devices industry. These Guidances represent the current thinking of regulatory agencies on a particular subject. It is to be noted that the term “Guidances” is used in the USA, whereas the term “Guidelines” is used in Europe.

History of COVID-19 vaccine development Scientific work to develop a vaccine for COVID-19

SARS-CoV-2, the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering the urgent international response to prepare for an outbreak and hasten development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

References

  1. ↑ ICH Good Clinical Practice January 1997
  2. ↑ US FDA Guidance for industry, January 2013
  3. ↑ "What is an eTMF system and why do you need one?". www.etmf.org. Archived from the original on 2012-03-30.
  4. ↑ US CFR 21 Part 11 April 2012
  5. ↑ EMA eSubmissions December 2008.
  6. ↑ AIIM ECM Report May 2013
  7. ↑ EMA Guideline, P.9, February 2013
  8. ↑ "Archived copy" (PDF). Food and Drug Administration . Archived from the original (PDF) on 2017-08-30. Retrieved 2019-12-16.{{cite web}}: CS1 maint: archived copy as title (link)
  9. ↑ "Part 11, Electronic Records; Electronic Signatures - Scope and Application". Food and Drug Administration . 11 June 2020.
  10. ↑ FDA Electronic records and signatures August 2003 Guidance
  11. ↑ "CareLex Builds Support for Developing Interoperability Standard for Clinical Trial Data Exchange".
  12. ↑ "The Start of a New Era for Clinical Trials". 7 October 2019.
  13. ↑ "OASIS Open: Committees".
  14. ↑ "OASIS Open: Committees".
  15. ↑ "OASIS Electronic Trial Master File (ETMF) Standard Technical Committee | Charter".
  16. ↑ "OASIS Electronic Trial Master File (ETMF) Standard TC | IPR".
  17. ↑ "CareLex Builds Support for Developing Interoperability Standard for Clinical Trial Data Exchange".
  18. ↑ "Sign up | LinkedIn".
  19. ↑ European Medicines Agency, 9. Problems found with Trial Master Files from GCP inspections, Jan 2013
  20. ↑ Outsourcing-Pharma.com. "eTMF market to grow sizably over next three years, ISR reports". Outsourcing-Pharma.com. Retrieved 2016-10-27.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.